Latest News
Featured News
Scancell Receives FDA Fast Track Designation for iSCIB1+
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Select the category
Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+
Director Dealing
Partnership with NHS Cancer Vaccine Launch Pad Enabling Fast-Tracked Access for Melanoma Patients
Scancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting
Issue of share options
Scancell to present translational data from the Phase 2 ongoing SCOPE trial of SCIB1 at the 2025 AACR IO conference
No results found.
Regulatory News Archive
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.